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Abstract 
 
It is very important to select new pharmaceutical products among the world's successful and best-selling products. What seems 
problematic in the development process of the portfolio of products is the analysis of potential and actual competitors and the 
rate of success of new products in achieving share from the pharmaceutical market.  For this purpose, experts of 
pharmaceutical industry have been consulted in determining the factors affecting the development of the portfolio of products. 
The results of the data analysis suggest that the criterion "three-past-year average sales of pharmaceutical companies" is the 
most important.  
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 Introduction 1.
 
Any organization is faced with certain goals, limitations, priorities, policies, opportunities and threats and problems, which 
it should take into consideration in its decision-making. An important subject in management and administration of 
organizations is decision-making, or put more accurately, assigning accurate decision-making tool to top managers of 
organizations to select the optimal or close-to-optimal portfolio of investment (Azar et al, 2012). Since it is very important 
to make optimal economic decisions in such an environment, one of the most influential decisions is about the portfolio of 
products. However, the capability of making the best possible decision (as the output) based on the past and present 
information and future predictions (as the input) is a complicated process.  
Decision-making techniques has attracted researchers' attention since the early 1970s (Wu & Zhang, (2011)) and 
optimization models have attracted mathematicians and industry practitioners since World War II. Since then, many 
people have tried to provide useful and optimal methods for planning and determining the portfolio of products. 
The base and foundation of this planning to determine the portfolio of products is formed by designing similar 
products Jiao et al. have described this issue well. The modeling of the design of similar products was set forth by Zhi-
hong et al. and was then presented by Jiao et al. 
Today, despite the abundant attempts made for the optimal selection of portfolio of pharmaceutical products, no 
research has unfortunately been conducted yet about the effective criteria of developing this portfolio. Therefore, it seems 
necessary to investigate this category in order to attain more effectiveness in the selection of pharmaceutical products 
and achieve more competitive advantage in pharmaceutical products. 
The first part of this study has dealt with a review of the literature and previous studies. The second part has dealt 
with the research methodology and the third part has determined the factors affecting the development of portfolio of 
pharmaceutical products besides making use of experts' viewpoints. Then, the implementation model was executed in 
Visual Promethee software, the results were analyzed and the output was confirmed. Finally, the results were analyzed 
and the conclusion was presented in the fourth part. 
 
 A Review of the Theoretical Fundamentals and Literature 2.
 
We will explain the portfolio of products of pharmaceutical companies and multi-criteria decision-making in this part. 
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Then, we will deal with some studies done for selection of the portfolio of products using multi-criteria decision-making 
methods. 
 
2.1 Portfolio of products of pharmaceutical companies 
 
Project portfolio refers to a set of projects in an economic unit and with the same strategic goals and common resources. 
The financial and physical resources of such projects are often quite limited and projects are competing with one another 
under the same management in order to attract these limited and rare resources. The process of evaluating, prioritizing 
and selecting the project is one of the most important and basic issues in project portfolio management. Portfolio 
management emphasizes that projects should be evaluated not only separately from one another, but also in the total set 
of projects, as they are hardly independent of one another by nature. 
In other words, the portfolio or portfolio of projects refers to a set of projects done under the management of a 
given organization. The process of selecting the portfolio of projects is a periodical activity in which a set of projects is 
selected among the proposed projects in order to help achieve the organization's predetermined goals without the use of 
extra resources. 
The pharmaceutical industry of the world has recently had a considerable growth in the amount of demand for 
generic (new) medicines in the pharmaceutical market of countries [Nassiri-Koopaei et al, 2014]. It seems that this status 
is considered the natural trend of the growth of generic medicines market and the pharmaceutical market of Iran is no 
exception to this rule. 
Since there is a considerable difference between generic pharmaceutical industry and brand in terms of the 
process of product development, the factories manufacturing generic products can provide customers with products with 
a comparable quality to the reference brand in a shorter period of time and with much lower cost and price and can 
considerably reduce the costs of the health system and household portfolio. 
Unlike brand industry in which the medicine's manufacturing company is in charge of the entire stages ranging 
from the discovery of molecule to the sales of the product in the market as well as all clinical trials, in generic industry the 
manufacturing company should only prove that the manufactured product of that company is like the product of the 
reference brand in terms of quality, bioequivalence studies, effectiveness and efficiency, and that the company is not 
responsible for performing clinical trials and the stages of discovery, research and development of primary molecule, 
which considerably reduces the cost and time of developing a new product. Therefore, the stage of new generic product 
selection for the product development process is also quite different from brand industry. 
The process of new (generic) product selection which is done among the successful and best-selling brand 
products is considered an important process, because due to the limitation of capital resources, the policy makers and 
managers of this industry stress the optimal allocation of resources to the projects of manufacturing new and efficient 
medicines which have priority in terms of profitability and health promotion in the society. 
Considering cases like this, which create problems in the process of producing selected products, it is necessary to 
analyze the competitors that present new products and to develop the portfolio of products with regard to the figures. 
 
2.2 Multi-criteria decision-making 
 
Multi-criteria decision-making is an important research area in decision-making science and is widely used in many fields 
such as economy and management. Several criteria of assessment rather than only one optimality assessment criterion 
are used in this type of decision-making. Decision-making models are of two main types: multi-objective decision-making 
and multi-attribute decision-making. Multi-objective models are used for design, whereas multi-attribute models are used 
to select the top alternative (Asgharpour, (2010). 
In multi-objective decision-making models, several objectives are simultaneously pursued for optimization and the 
assessment scale foe each objective may be different from that for other objectives. However, multi-attribute decision-
making models deal with selecting or ranking one alternative from among several alternatives evacuated with n-
alternatives. 
Many models for selection of the portfolio of products have been presented so far, the similarity of which is 
tendency to multi-criteria models (Mohaghar & Mostafavi (2007)). Considering the topic studied in this research, the 
decision-making in this research is multi-criteria decision-making. 
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2.3 Previous Studies 
 
Nowadays, there is an increasing need for the development of new markets and products (Cooper & Kleinschmidt, 
(1993)), and the companies that are active in pharmaceutical industry arena need the market development strategy in 
order to create sustainable competitive advantage. Therefore, the marketers of this arena should focus more on the 
development of their own marketing models which can help them understand, interpret and predict the events and market 
performance (Ghasemi et al, 2009). 
The increasing competition in business makes companies compete with one another at the national and 
international levels in order to survive the market (Sinaei & Rashidizadeh, (2010)). Today, achieving a top competitive 
position and conquering the competitors or following the competitive goals are among the main concerns of companies, 
especially those active in pharmaceutical products. However, what financial and non-financial consequences the 
achievement of a top competitive position can have for these companies is a contested issue. Making attempts to 
increase the market share, make customers loyal, increase the quality of the product, reduce the cost price and improve 
and establish the financial position of companies amounts to companies' trying to promote the competitive position and 
achieve a better competitive position in the competitive environment of the present market. 
Competitiveness can generally be regarded as capabilities that a business, industry, region or country has and can 
maintain in order to create a high return rate at the international competition level. In other words, competitiveness refers 
to the ability to increase market share, get profit, increase the added value and stay in the international competition arena 
for a long period of time (Man et al, 2002). 
Another controversial issue is organizational strategy. Organizational strategy refers to making the optimal and 
complete use of all capacities in order to achieve the prospects and main objectives of organizations by taking advantage 
of different options and tools. 
As one of the main inputs of medical cares, medicine has an outstanding feature that distinguishes its position from 
that of other sectors (Kebriaeezadeh et al, 2010). The pharmaceutical costs and its other related costs in Iran and many 
other developing countries constitute about 30% of the total costs of medical cares and approximately 50% of the total 
costs of outpatient health and medical cares. 
We have dealt in this research with the detection and prioritization of the key factors affecting competition in 
pharmaceutical industry of the country. The pharmaceutical industry has changed a lot during the past ten years (Munos, 
(2009)) and most of the changes have occurred due to research and development activities [12.40], uncertainty in the 
process of medicine development, shortage of new products (Engelhardt & Garrett, (2008)), too fast mergers (Schweizer, 
(2005)) fast development of public markets (Karhu & Yla-Kojola, (2010)), and finally an increase in global competition and 
technology development (McAdam & Barron, (2002)). 
Considering the increasing competition in medicines, the performance of pharmaceutical companies should be 
accurate, fast and futuristic. Moreover, due to the intensely competitive environment, it is very important to identify the 
factors influencing competition in pharmaceutical industry in the international market (Kesiþ, (2009)). The pharmaceutical 
industry of Iran has had a growth of over 28.38 percent during the last 10 years. The medicines produced in Iran during 
these years have cost 1.69 billion dollars (Shabaninejad et al, 2014). 
It should be noted that based on the existing evidence and according to the investigations approving of the lack of 
a document or report in previous studies to evaluate and rank companies with favorable parameters, it seems that this 
research has been designed and documented for this purpose for the first time. Although pharmaceutical companies 
periodically analyze their competitors and their changes of the portfolio, their reports are not definitely publicized. No 
report about this was actually observed in different websites such as IRANDOC and CIVILIKA. 
 
 Research Methodology 3.
 
The present research is an applied research in terms of purpose, a qualitative one in terms of nature and research 
method and a descriptive-survey and causal research in type. 
The research population includes 374 medicine exporting and importing companies in Iran, the figures and 
information needed by these companies were obtained from the official statistics of the Ministry of Health, Treatment and 
Medical Education available in the website of this ministry during the recent-ten-year interval (between 2004 and 2013). 
For data collection, the librarian method and field method were used respectively for the theoretical fundamentals and 
extraction of the criteria factors, and experts' views were used for confirmation of the factors and criteria of the research 
model, and for the ranking of the factors and criteria. 
The members of the team of experts were 20 managers, all with PhD degrees, from the Organization of Food and 
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Drug and the Ministry of Health, Treatment and Medical Education with at least five years of experience in the 
Pharmaceutical Industry of the country. 
Due to the extensive statistical population and the problems of entering data to the software, the sample size can 
be selected from the population in one of the following two states: 
A: 52 top companies which have 80% of the sales share from the pharmaceutical market in 2013. 
B: 20 top companies which have 50% of the sales share from the pharmaceutical market in 2013. 
After frequent examinations, consulting the experts and ranking the companies in terms of sales share in 2013, the 
second state was eventually selected. Thus, 20 top pharmaceutical companies of the country, ranked in terms of sales 
share in 2013, are as follow: 
Cobel Daru, Behestan Daru, Darupakhsh, Eksir, Farabi, Abidi, Tehran Shimi, Alborz Daru, Dana, Actover, Jaber 
ebn Hayan, Shafayab Gostar, Abureihan, Sina Daru, K.B.C., Sobhan Daru, Caspian Tamin, Cinnagen, Osveh, Iran 
Hormone. 
The data analysis method used in the research to measure frequencies and averages is correlation and regression 
at the same time, and Promethee Technique and Visual Promethee Software have been used foe the comparison of the 
companies in terms of the criteria of success, and Shannon Entropy Method has been used for weighting the criteria. 
Figure 1 shows the stages of the research execution. 
 
 
 
Figure 1: stages of the research execution 
 
3.1 Entropy Method 
 
For multi-criteria decision-makings, the criterion weight is an important factor for determining the relative importance of 
criteria, and Shannon Entropy Method is one of the methods of determining weights. The term "entropy" meaning 
disorder, was first posed by Rudolf Clausius in 1865 in the field of thermodynamics and by Claude Shannon in 1978 in 
the ICT field (Zhang, et al, 2010). After Shannon expressed the entropy of information in his article "Mathematical Theory 
of Communication", it was extensively used afterwards in different fields such as engineering, management and so on 
(Wu & Zhang, (2011)). Shannon Entropy Method is an appropriate method for measuring the relative importance of 
attributes and transferring the intrinsic value of data to the decision-maker (Wang & Lee, (2009)). Entropy is a good tool 
for evaluating the weight of the criteria of a decision problem which is defined as a complete matrix (Shanian & 
Savadogo, (2006)). This method calculates the weights of each criterion in terms of distribution of the criterion values. 
The more distributed the values of a criterion is, the more important that cri will be (Zhao et al, 2010). If we have a 
decision matrix with the degree of m×n, such that m represents the number of alternatives, shown by A1 to Am, and that 
n represents the number of criteria, displayed by C1 to Cn, we use Entropy Method to calculate the weight of the criteria 
in the following way ((Wang et al, 2008), (Zhi-hong et al, 2006)): 
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Figure 2: formulas of computing the weight of criteria using Entropy Method 
 
a- At first, the matrix is normalized using this formula (figure 2). Based on this formula, the value of elements of 
each matrix is divided by the sum of the column. 
b- Computing the entropy value: Ej, (ln) logarithm is based on p-value. 
c- Computing the degree of deviation: d 
d- Computing the criteria weight: w 
e- Adjusting the criteria weight 
 
3.2 Promethee Method 
 
Promethee Method is one of the multi-criteria decision-making methods described in the following way. Suppose that A is 
a set of alternatives among which one alternative is to be selected. Assuming that there is k effective criteria in decision-
making, foe each alternative Aa, the value of fj (a) represents the j-th criterion value in alternative a. Ranking is done at 
three stages [16]: 
First stage – creating generalized criterion: the Pj preference function is given to each one of j criteria. The value of 
Pj (a, b) is computed for each alternative pair. This value ranges from zero to one. If the relation fj (a) =fj (b) exists, the 
value of Pj (a, b) becomes zero and when fj (a)-fj (b) increases, this value also increases. When the difference becomes 
high enough, the value of Pj (a, b) also becomes 1.  Different forms can be supposed for Pj function, which depends on 
modeling the jth criterion. As shown in Table 1, Promethee Method proposes six generalized criteria to decision-makers 
for preference function (Pourreza et al, 2014). 
 
Table 1: description of the generalized criteria 
 
Criterion name relation description 
Usual 
Preference  If the two alternatives have the same score, there will be no difference. 
U-shape 
preference  
There will be no difference until the difference of the scores of the two alternatives is less than q. 
Linear 
Preference  
With a change of scores in the distance of zero and p, the priority will change in linear form. If the 
difference is more than p, the considered alternative has complete priority. 
Level 
Preference 
 
If the difference of scores is less than q, there will be no difference. If the difference is between the 
values of p and q, there will be a comparative advantage, and if the rate of difference is more than p, 
there will be complete priority. 
V-shape 
Preference 
 
If the difference of scores of the two alternatives is less than q, there will be no difference. With a 
change of scores within the distance of p to q, the priority rate will change in linear form. If the 
distance rate is more than p, there is complete priority. 
Gaussian 
preference 
With the difference among the scores of alternatives, the priority rate will increase according to the 
relation. 
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The second stage – determining the relation of ranking among the alternatives: the total rate of priority ʌ (a, b) for each 
alternative a is computed over the alternative b. the more the amount of ʌ (a,b), the more preferable the alternative a will 
be.ʌ (a, b) is computed in the following way: 
 
The third stage – evaluating the ranking for determining the final answer ʌ (a, b): this represents the priority degree 
of alternative an in ratio to alternative b. the output flow is computed in order to determine the total preference power of 
alternative an over the other alternatives: 
Positive ranking flow or output flow 
 
This flow shows how preferable alternative is in ratio to other alternatives. This flow is actually the power of 
alternative a. The largest  (+ĳ a) means the best alternative. The preference rate of other alternatives over alternative a, 
which is called the input flow, is computed in the following way: 
Negative ranking flow or the input flow 
  
This flow shows how preferable other alternatives are over alternative a. this flow actually represents weakness of 
alternative a. The smallest ĳ-(a) shows the best alternative. Therefore, one can do a detailed ranking by separately 
examining the two flows of ĳ+ and ĳ- (ranking of PROMETHEE I). For the complete ranking of alternatives, the net flow 
of ranking should be defined for each alternative (ranking of PROMETHEE II): 
 
This flow is the result of the balance of positive and negative ranking flows. The higher net flow shows the higher 
alternative. 
Among the important advantages of Promethee Method are simplicity, clarity and reliability of its results. This 
method can do the process of evaluation on a limited set of limited alternatives in the form of a detailed or complete 
ranking. The clear effect of each criterion and its weight on the answers, the high performance and efficiency of algorithm 
in this method despite its simplicity and its foundation based on the importance of the performance difference between 
two answers – distinguish this method from Analytic Hierarchy Approach (Cooper & Kleinschmidt, (1993)). 
 
 Findings 4.
 
4.1 Definition of the criteria 
 
The present research has been done based on the ten-year sales statistics of the active pharmaceutical companies in the 
country between 2004 and 2013 and has regarded 10 variables as the factors affecting the development of the portfolio 
of products of pharmaceutical companies after the studies and investigations, as observed in the conceptual model 
shown in Figure 3. 
 
 
Figure 3: factors affecting the development of portfolio of products of pharmaceutical companies 
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In this study, the experts included 20 medical and health sector managers with at least 25 years of presence in the 
industry that questionnaires have been distributed among them. About the validity and reliability of the distributed 
questionnaire, The Cronbach's alpha coefficient method and SPSS software were used and the Cronbach's alpha 
coefficient was estimated to be 0.868. The formula for calculating Cronbach's alpha coefficient is as follows: K is the 
number of questions in the questionnaire, s2 is the total variance of questions and si2 is the variance of each question. 
 
 
4.2 Computing the criteria weight using Entropy Method 
 
Due to the importance and advantages of Entropy Method, this method is used for computing the criteria weights. 
Different stages of this method include computation of Ej, and dj has been done using Excel Software and has been 
computed using the formula of WI values (Table 2). The adjusted weights of wj were finally obtained via the subjective 
judgments of experts, as shown in Table 3. 
 
Table 2: weights according to experts' views 
 
WeightRankCriterion
21Variety of shape
169New portfolio
106Total portfolio
74pioneer
73Number of distributions
85Market share
2210Average of 3-year sales
127New market share
138New sales
32competitors
 
Table 3: adjusted weights 
 
WeightRankCriterion
0.0111Variety of shape
0.117New portfolio
0.0995Total portfolio
0.0614pioneer
0.0373Number of distributions
0.1066Market share
0.2910Average of 3-year sales
0.1278New market share
0.1319New sales
0.0272competitors
 
 
4.3 Data collection and decision matrix 
 
In this study, after determining the criteria of the factors affecting the development of the pharmaceutical companies' 
portfolio of products, a multi-criteria decision-making model based on Promethee Method has been designed. 
After determining the criteria weights, Promethee method has been used to help rank the companies and 
determine their priority based on the ten-fold criteria. Visual Promethee Software has been utilized for this purpose. At the 
beginning, the number of alternatives and then criteria are determined. At the next stage, the values of the decision 
matrix are entered into the software. 
Therefore, decision matrix is formed based on the ten criteria of decision-making and 20 top pharmaceutical 
companies of the country (Co1 to Co20 or A1 to A20 in decision matrix), as shown in Table 4. 
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Table 4: Decision-making matrix 
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1271,00 1153959,38 0,0511748742,510,4262,0061,00596,00142,00106,00Co1 
2901,00 752626,11 0,038449642,920,3052,0079,001071,00232,00122,00Co2 
8134,00 258193,95 0,0111168683,740,4825,0033,001987,00185,00158,00Co3 
5868,00 792195,23 0,0310591403,750,4433,0040,001169,00147,00101,00Co4 
2621,00 101711,16 0,008823186,560,3969,0017,00565,0090,0053,00Co5 
5589,00 282415,34 0,014104432,510,1654,0042,001018,00153,0067,00Co6 
4991,00 363568,11 0,016280372,520,2465,0015,00910,00117,0087,00Co7 
257,00 308938,01 0,015449201,300,2167,0023,00728,00137,0091,00Co8 
1709,00 178095,14 0,014731814,340,1880,0033,00518,00107,0068,00Co9 
2611,00 711030,95 0,012523334,740,1039,0010,00416,00102,0070,00Co10 
2091,00 309649,12 0,017962676,970,3471,0027,00769,00124,00112,00Co11 
687,00 702979,34 0,037270815,380,2659,00106,00958,00260,00107,00Co12 
3130,00 84990,82 0,003897604,970,1527,0040,001064,00164,0071,00Co13 
318,00 1235,42 0,003927,550,006,000,006,002,004,00Co14 
762,00 779386,27 0,032703056,270,1149,0012,00207,0096,0049,00Co15 
5218,00 79520,00 0,003982109,540,1666,0017,00968,00112,0055,00Co16 
211,00 42583,49 0,003655165,870,1442,008,00758,0058,0064,00Co17 
76,00 208732,20 0,012157333,200,0710,000,0022,007,0016,00Co18 
3030,00 534822,74 0,024240322,280,1563,0045,00645,00112,0060,00Co19 
2064,00 78718,03 0,002894435,850,1145,0020,00578,0076,0030,00Co20 
 
4.4 Prioritization of the alternatives using Promethee Method 
 
In this part of the research, we apply the Visual Promethee Software and do the computations, and thus obtain the 
required outputs or ranking of 20 pharmaceutical companies including both manufacturing and importing companies as 
shown in the following: 
 
 
 
Figure 4: Detailed ranking using Promethee Method 
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Figure 5: Complete Ranking using Promethee Method  
 
 
 
Figure 6: The Promethee Flow Table 
 
 
 
Figure 7: Gaia Visual Module 
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With regard to the input values in the software, as shown in figure 6, the highest rank belongs to Col Company with net ĳ 
of 0.7080. (net ĳ shows the software preference in choosing the options and the higher its value is, the better the 
preference sign will be), and the lowest rank belongs to Co14 with net ĳ of 0.8942.  
In figure 7, Gaia Visual Module, the line orientation with the circle end shows movement toward the best 
preference (Co1), and alternatives which are in the opposite direction of the best case show the worst preference. Using 
this figure, one can see that Co1, Co4, Co2 and Co12 have a high preference due to their having positive net ĳ, while 
Co14, Co17, Co18 and Co20 have the lowest preference as they have negative net  ĳ. 
 
4.5 Validation of the model  
 
The review done by industry experts on the obtained results showed that the ranking of the companies using the 
proposed model is confirmed by them, but determining the parameters of evaluation in ranking the companies is of great 
importance. For example, when the parameter of the medicine manufacturing or importing company's activity history is 
one of the ranking parameters, companies with low experience of manufacturing and high volume of sales, without many 
competitors, get a good rank during the recent years and they can be called newly emerging competitors. 
Therefore, considering the variety of influential parameters in ranking, it can be said that the above-mentioned 
model is dependent on the parameters of evaluation and determining the parameters of evaluation is a separate topic 
from the research issue. 
 
 Conclusion  5.
 
We tried in this research to identify the criteria affecting the development of the portfolio of products of Iran's top 
pharmaceutical companies by examining the pharmaceutical industry of the country and using the views and experiences 
of experts from this industry, and rank the pharmaceutical companies including the manufacturing and importing ones 
using the multi-criteria decision-making method of Promethee by weighting the criteria using Shannon Entropy Method. 
The results of analyzing the data suggest that the criterion "the average sales of pharmaceutical companies during 
the last three years" has the most importance, and the criterion "variety of medicine's shape" has the least importance. 
Researchers can investigate the impact of different criteria on the pharmaceutical companies' portfolio of products 
in future by studying other performance indicators of companies, especially the important indicators in cases of 
companies' profit and loss such as net profit, the value of assets, the number of human resources, the number of 
investments, shareholders' contribution and bank debt,  
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